The Board of Directors has in accordance with its guidelines and instructions assigned to the Company’s CEO, Tomas Blomquist, to manage the Company’s affaires. The CEO, and the Executive Management under the supervision of the CEO, is responsible for the Group’s day to day business and management. The CEO reports by regular intervals to the Board of Directors how the Company’s business perform, financial result and other issues important to the Company.
Tomas Blomquist is CEO & President at Biotage as of November 6, 2019. Mr. Blomquist is born in 1970 and has more than 25 years of international experience within the healthcare industry, particularly in the Diagnostics & Medtech area. He has held executive positions at Abbott, Roche, Johnson & Johnson and Analyticon Biotechnologies. Mr. Blomquist has built sustainable high performing organizations and profitable growth companies through direct and indirect sales channels in more than 100 countries. He has extensive expertise in corporate strategy, people development, business model innovation, Internationalization, organizational design and commercialization. Mr. Blomquist is a former middle-distance runner, lives in Stockholm and is passionate to creating value and results to personnel, customers, environment, society and shareholders.
Annette Colin is the CFO at Biotage as of April 1st, 2020. Annette is born in 1965 and she has more than 25 years of experience in executive positions as CEO, CFO, COO, Group Financial Controller and Tax Manager, including 14 years in Life Science. Annette has been part of fast-growing companies and organizations and has long experience in building strategic plans, leadership development and streamlining infrastructure. She has been Involved in several M&A and IPO transactions and worked with both Venture Capital and Private Equity owners but the majority in listed companies. Most recent assignments include Annexin Pharmaceuticals AB (publ) Observe Medical International (publ), Stille AB (publ), Lindab International AB (publ), Perbio Science AB (publ) and EY. She has also experience as an investor and from board assignments. Annette has education in Business Administration, marketing, organizational-learn and law at Lund University, Sweden.
Lars Bäckman has been with Biotage since January 2007 as the VP of Corporate Development. Prior joining Biotage, Lars held the position as SVP of Corporate Development at Affibody. Lars was appointed Chief Legal Officer as of 1 January 2020. He has previous experiences acting as a lawyer at the Swedish law firm Hamilton & Co, specialized in Corporate Finance and Mergers & Acquisitions, and from Venture Management at the Business Development firm Googol. He is a Board member in Chreto A/S. Mr. Bäckman holds a LLM from the Stockholm University and was born in 1961.